- Home
- HTH vs AKRO Comparison
HTH vs AKRO Comparison
Compare HTH & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- AKRO
- Stock Information
- Founded
- HTH 1998
- AKRO 2017
- Country
- HTH United States
- AKRO United States
- Employees
- HTH N/A
- AKRO N/A
- Industry
- HTH Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HTH Finance
- AKRO Health Care
- Exchange
- HTH Nasdaq
- AKRO Nasdaq
- Market Cap
- HTH 1.9B
- AKRO 3.9B
- IPO Year
- HTH 2004
- AKRO 2019
- Fundamental
- Price
- HTH $31.91
- AKRO $51.77
- Analyst Decision
- HTH Hold
- AKRO Strong Buy
- Analyst Count
- HTH 2
- AKRO 6
- Target Price
- HTH $33.00
- AKRO $82.50
- AVG Volume (30 Days)
- HTH 419.0K
- AKRO 1.7M
- Earning Date
- HTH 07-24-2025
- AKRO 08-08-2025
- Dividend Yield
- HTH 2.26%
- AKRO N/A
- EPS Growth
- HTH 15.07
- AKRO N/A
- EPS
- HTH 1.97
- AKRO N/A
- Revenue
- HTH $1,208,822,000.00
- AKRO N/A
- Revenue This Year
- HTH N/A
- AKRO N/A
- Revenue Next Year
- HTH $1.36
- AKRO N/A
- P/E Ratio
- HTH $16.22
- AKRO N/A
- Revenue Growth
- HTH 2.13
- AKRO N/A
- 52 Week Low
- HTH $26.67
- AKRO $21.02
- 52 Week High
- HTH $35.32
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- HTH 69.23
- AKRO 49.14
- Support Level
- HTH $30.20
- AKRO $51.08
- Resistance Level
- HTH $30.54
- AKRO $57.35
- Average True Range (ATR)
- HTH 0.56
- AKRO 2.21
- MACD
- HTH 0.23
- AKRO -0.81
- Stochastic Oscillator
- HTH 92.28
- AKRO 11.08
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.